| Identification | Back Directory | [Name]
SC 144 | [CAS]
895158-95-9 | [Synonyms]
SC144
SC-144
SC 144
CS-805
SC 144; SC144
SC144;SC-144;SC 144
2-(7-fluoropyrrolo[1,2-a]quinoxalin-4-yl)hydrazide
N'-(7-Fluoropyrrolo[1,2-a]quinoxalin-4-yl)-2-pyrazinecarbohydrazide
Pyrazinecarboxylic acid 2-(7-fluoropyrrolo[1,2-a]quinoxalin-4-yl)hydrazide
2-Pyrazinecarboxylic acid, 2-(7-fluoropyrrolo[1,2-a]quinoxalin-4-yl)hydrazide | [Molecular Formula]
C16H11FN6O | [MDL Number]
MFCD25976763 | [MOL File]
895158-95-9.mol | [Molecular Weight]
322.3 |
| Chemical Properties | Back Directory | [density ]
1.53±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
insoluble in EtOH; insoluble in H2O; ≥16.1 mg/mL in DMSO | [form ]
solid | [pka]
8.87±0.43(Predicted) | [color ]
Light yellow to yellow |
| Hazard Information | Back Directory | [Uses]
SC144 is an orally active small-molecule gp130 inhibitor. | [Biological Activity]
sc144 is an inhibitor of gp130 with ic50 values of 0.43 μmol/l and 0.88 μmol/l in nci/adr-res and hey cell lines, respectively [1].sc144 is a ?rst-in-class small-molecule gp130 inhibitor with oral activity in ovarian cancer. it can substantially increase the phosphorylation of gp130 (s782) in both ovcar-8 and caov-3 cells in a time- and dose-dependent manner. the increase phosphorylation then suppresses stat3 signaling pathway since the constitutive stat3 activation is maintained by extracellular gp130 ligands, besides that, sc144 also causes substantial cell apoptosis in these cells. [1].apart from the effect on gp130, it has been reported that sc144 can directly bind and stabilize il-24 in cancer cells. additionally, sc144 has shown to have effects on cell cycle perturbation and apoptosis induction [2].sc144 may also have other cellular protein targets, resulting in multiple potential molecular mechanisms. sc144’s anticancer potency may be a sum of these effects [2]. | [in vivo]
SC144 (10 mg/kg; i.p.; daily for 58 days) suppresses tumor growth in human ovariancancer xenografts[1].
?
SC144 (100 mg/kg;p.o.; daily for 35 days) treatment shows the average tumor volume in mice 82% smaller than that in the control group[1]. | Animal Model: | Athymic mice (human ovarian cancer xenograft)[1] | | Dosage: | 10 mg/kg | | Administration: | I.p; daily for 58 days | | Result: | Significantly inhibited tumor growth by about 73%.
|
| [IC 50]
IL6-beta | [References]
[1] shili xu, fedora grande, antonio garofalo, et al. discovery of a novel orally active small-molecule gp130 inhibitor for the treatment of ovarian cancer. molecular cancer therapeutics. 2013 (12): 937-949.
[2] shili xu, takashi oshima, toshio imada, munetaka masuda, bikash debnath, fedora grande, antonio garofalo, nouri neamati. stabilization of mda-7/il-24 for colon cancer therapy. cancer letters. 2013 feb(335):421-430. |
|
|